HEMLIBRA® (emicizumab-kxwh)
For US Patients and Caregivers

FATALITIES IN EMICIZUMAB-KXWH CLINICAL TRIALS, EXPANDED ACCESS, COMPASSIONATE USE, AND AFTER FDA APPROVAL1–3

- Genentech and Roche initiated pivotal clinical trials for people with hemophilia A with factor VIII inhibitors in 2015, and also made emicizumab-kxwh available through the expanded access program, and requests to Roche for compassionate use. In November 2017, the FDA approved emicizumab-kxwh for the treatment of people with hemophilia A with factor VIII inhibitors, and in October 2018, the FDA expanded the approval of emicizumab-kxwh to include the treatment of people with hemophilia A without factor VIII inhibitors.

- Patient safety is of the highest importance to us. Genentech and Roche are saddened by any reports of deaths and take all reports of death and safety events seriously.
  - All fatalities are evaluated through Genentech and Roche drug safety and reported to regulatory authorities in strict accordance with guidelines and requirements. Systems and processes are in place to monitor the safety of all our medicines, including emicizumab-kxwh, on an ongoing basis.
  - This website includes all reported fatalities in people who received emicizumab-kxwh, whether or not the cause of death is related to emicizumab-kxwh. In none of the reported cases had the causality been assessed as related to emicizumab-kxwh.
  - The 44 fatal cases occurred in Asia, Australia, Europe, and North America.1

Fatalities Reported/Verified at Data Cutoff of June 30, 20201–3

<table>
<thead>
<tr>
<th>Clinical Trials</th>
<th>Number of Fatalities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Expanded Access</td>
<td>3* (HAVEN 1 and STASEY trials)</td>
</tr>
<tr>
<td>Compassionate Use</td>
<td>1</td>
</tr>
<tr>
<td>After FDA Approval</td>
<td>37</td>
</tr>
</tbody>
</table>

Note: Among 44 fatalities, emicizumab-kxwh was used to treat hemophilia A with inhibitors in 16 people, hemophilia A without inhibitors in 13 people, hemophilia A with inhibitor status not reported in 3 people, acquired hemophilia A (not an FDA-approved use) in 9 people, and the indication was not reported in 3 people.

1One death occurred in HAVEN 1 and 2 deaths occurred in STASEY. HAVEN 1 was a Phase 3 clinical trial that studied emicizumab in adults and adolescents ≥12 years of age with hemophilia A with factor VIII inhibitors. STASEY is an ongoing, Ex-US, Phase 3b clinical trial studying the safety and tolerability of emicizumab in adults and adolescents ≥12 years of age with hemophilia A with factor VIII inhibitors.

Patient safety is of the highest importance to us. We take all reports of safety events very seriously and encourage anyone who knows of a side effect in a patient on emicizumab-kxwh to report the event to Genentech/Roche. We have systems and processes in place to collect, analyze, and monitor side effects and report events to the FDA per regulations.

Due to the voluntary nature of postmarketing spontaneous side effect reports, information may be missing or incomplete. Genentech/Roche has limited ability to ascertain and verify information from these side effect reports, and reporters, including healthcare providers, are not obligated to share these details with Genentech/Roche. Furthermore, reporters themselves may not have access to all of the information regarding a patient’s care for these events. Genentech/Roche does not provide additional details related to side effects reported in the postmarketing setting, because the level of detail available and Genentech/Roche’s ability to confirm individual details is variable. In addition, patient privacy is very important to Genentech/Roche, therefore we are careful not to disclose specific details about a side effect that could jeopardize the privacy of either the patient or their family, or breach patient confidentiality. As a result of the variable level of detail in such spontaneously reported data, Genentech/Roche will provide information on the number of verified reports on this website without additional reported details related to events.

If any side effect in a person taking emicizumab-kxwh impacts the overall safety profile of the medicine, we will share this information as quickly as possible and in accordance with any FDA requirements.

Your healthcare provider should be the primary source of information about your medical condition and the safe and effective use of any medicine, including emicizumab-kxwh.

You may contact our Medical Communications department with questions specific to this site:
(800) 821-8590, 5:00 AM – 5:00 PM PST.

References

HEMLIBRA® is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

What is the most important information I should know about HEMLIBRA?

HEMLIBRA increases the potential for your blood to clot. Carefully follow your healthcare provider’s instructions regarding when to use an on-demand bypassing agent or factor VIII, and the dose and schedule to use for breakthrough bleed treatment. HEMLIBRA may cause the following serious side effects when used with activated prothrombin complex concentrate (aPCC; FEIBA®), including:

- **Thrombotic microangiopathy (TMA).** This is a condition involving blood clots and injury to small blood vessels that may cause harm to your kidneys, brain, and other organs. Get medical help right away if you have any of the following signs or symptoms during or after treatment with HEMLIBRA:
  - Confusion
  - Weakness
  - Swelling of arms and legs
  - Yellowing of skin and eyes
  - Stomach (abdomen) or back pain

- **Blood clots (thrombotic events).** Blood clots may form in blood vessels in your arm, leg, lung or head. Get medical help right away if you have any of these signs or symptoms of blood clots during or after treatment with HEMLIBRA:
  - Swelling in arms or legs
  - Pain or redness in your arms or legs
  - Shortness of breath
  - Chest pain or tightness
  - Fast heart rate
  - Cough up blood

If aPCC (FEIBA®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (FEIBA®) total.

You may report side effects to the FDA at (800) 1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 235-4555, 24 hrs/day, 7 days/week.

Return to Homepage by clicking here.